NCT03556228 2025-12-11VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLCPhase 1/2 Recruiting242 enrolled
NCT05941507 2025-09-24A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsLigaChem Biosciences, Inc.Phase 1/2 Recruiting300 enrolled
NCT03602079 2023-08-03Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneKlus Pharma Inc.Phase 1/2 Completed49 enrolled
NCT01806675 2019-10-0318F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyStanford UniversityPhase 1/2 Completed25 enrolled 14 charts
NCT00101348 2014-06-11Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/2 Completed66 enrolled